HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function
Sponsor: Eurofins Optimed
Terminated
Due to other Phase 3 trial failure to meet primary endpoint
Other terminated trials from Eurofins Optimed
More terminations from Eurofins Optimed
A PHASE1 clinical study on Healthy Volunteers and Hepatic Impairment of Moderate Child Pugh Category, this trial is terminated or withdrawn. The trial is conducted by Eurofins Optimed and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE1
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eurofins Optimed
- MedDay Pharmaceuticals SA
For direct contact, visit the study record on ClinicalTrials.gov .